Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individual albuminuria response to dapagliflozin in type 2 diabetes
NL-OMON50915Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and albuminuria (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change in first morning urinary albumin-to-creatinine ratio. Started May 2021; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)albuminuria
Beyond the preview
Go deeper on NL-OMON50915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50915.